Stockreport

Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF General and Administrative Expenses: $33.9 million for the year ended December 31, 2025, compared to $29 million in 2024. Net Loss: $109 million or $0.34 per share fo [Read more]